搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按时间排序
按相关度排序
13 天
Stifel维持Blueprint Medicines买入评级,目标价155美元
周四,Stifel重申了对Blueprint Medicines (NASDAQ:BPMC)股票的买入评级,目标价为155.00美元。该公司的评论强调了Blueprint Medicines在过敏和炎症市场的进展,特别是其主打产品Ayvakit的商业成功。
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
今日热点
Court filing made public
Helene's wake
Walz, Vance VP debate
5 Chinese nationals charged
MA new gun law takes effect
CA deepfakes law blocked
Voyager 2 tool turned off
Murdaugh's appeal rejected
Bank of America outage
Election betting allowed
Sued over inmate call rules
Ex-detective denied parole
US diagnostic errors study
May face additional charges
Golf Hall of Famer dies
Strike leads to panic-buying
California gang busted
Dream fire coach Wright
ABC News layoffs
Maui wildfire cause report
WW2-era bomb explodes
AG appeals abortion ruling
Factory probed after Helene
Can't sue Uber over crash
‘Ryan's Hope' actor dies
Valuation reaches $157B
反馈